Methylphenidate for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
- PMID: 27163989
- DOI: 10.1001/jama.2016.3611
Methylphenidate for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
Abstract
Clinical question: Is treatment with methylphenidate associated with benefits or harms for children and adolescents with attention-deficit/hyperactivity disorder (ADHD)?
Bottom line: Methylphenidate is associated with improvement in ADHD symptoms, general behavior, and quality of life; however, due to the very low quality of the evidence, the magnitude of the associated improvement is uncertain. Methylphenidate was associated with an increased risk of nonserious adverse events. There are too few data to assess the association with serious adverse events.
Comment in
-
Quantifying the Benefits and Risks of Methylphenidate as Treatment for Childhood Attention-Deficit/Hyperactivity Disorder.JAMA. 2016 May 10;315(18):1953-5. doi: 10.1001/jama.2016.3427. JAMA. 2016. PMID: 27163984 No abstract available.
-
Methylphenidate for Attention-Deficit/Hyperactivity Disorder.JAMA. 2016 Sep 6;316(9):994-5. doi: 10.1001/jama.2016.10279. JAMA. 2016. PMID: 27599342 No abstract available.
Comment on
-
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).Cochrane Database Syst Rev. 2015 Nov 25;2015(11):CD009885. doi: 10.1002/14651858.CD009885.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2023 Mar 27;3:CD009885. doi: 10.1002/14651858.CD009885.pub3. PMID: 26599576 Free PMC article. Updated.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
